How to read an EUA letter of authorization

An Emergency Use Authorization gets talked about like an approval, especially once a product is already in use. The letter itself doesn’t say that, and the gap between how an EUA is discussed and what it actually is matters — for labeling, for liability, and for knowing when the authorization can disappear.

What the letter is actually granting

An EUA letter authorizes a specific product, for a specific use, in a specific population, for the duration of a declared emergency — not a general approval that happens to apply broadly. Read closely, the letter is explicit about scope: an authorized use for one indication doesn’t extend to another, and an authorization for one product doesn’t cover a manufacturing or formulation change without FDA revisiting it. That specificity is easy to lose once a product has been in circulation for a while and the coverage has simplified it down to “authorized” — the same flattening that happens to other FDA designations that aren’t approvals either.

The four findings behind every authorization

Section 564 of the FD&C Act (21 U.S.C. § 360bbb-3) doesn’t let FDA authorize a product because an emergency exists and something might help. The agency has to conclude, specifically, that the agent involved can cause a serious or life-threatening disease or condition; that the totality of the available scientific evidence — which can include data short of what a full approval would require — makes it reasonable to believe the product may be effective; that the known and potential benefits outweigh the known and potential risks; and that no adequate, approved, and available alternative exists. That last criterion is why an EUA for a given use can disappear once an approved alternative reaches the market, even if nothing about the authorized product changed.

The conditions are where the obligations live

An authorization letter comes with specific conditions attached, and they’re the part worth reading past the headline grant: required fact sheets for providers and recipients, adverse-event and other safety reporting, recordkeeping, and often restrictions on who can prescribe or administer the product. None of that is optional because the underlying product was never approved — if anything, the conditions are doing some of the work an approval’s standard postmarket framework would otherwise do. FDA also tracks every change to the authorization the same way it tracks the original grant: through a Federal Register notice explaining what changed and why.

An EUA is a narrower, more conditional grant than the headline suggests, built around four specific findings and a set of obligations that don’t end at authorization. Reading the letter itself — not the press release describing it — is a small, specific case of reading primary sources before repeating someone else’s summary of them.